Skip to main content
Equibles

Roberto Cuca

CFO

TELA Bio, Inc. (TELA)

COO

TELA Bio, Inc. (TELA)

Chief Accounting Officer

TELA Bio, Inc. (TELA)

Equibles does not estimate personal net worth.

Get an email with a short summary when TELA Bio, Inc. publishes a filing, an earnings call transcript or a press release.

Get TELA alerts

About Roberto Cuca

Roberto Cuca is recorded as COO and Chief Accounting Officer at TELA Bio, Inc. (TELA) since September 27, 2021 and CFO at TELA Bio, Inc. (TELA). The newest filing on record that lists Roberto Cuca as CFO at TELA Bio, Inc. (TELA) is dated April 30, 2026. Roberto Cuca has spoken on 19 earnings calls across 1 company, most recently for TELA Bio, Inc. on May 12, 2026. TELA Bio, Inc. is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at TELA Bio, Inc. includes Heather Getz (CEO and Board Member), Doug Evans (Chairman), Paul Talmo (CTO) and 7 others.

Roberto Cuca on recent calls

“Revenue for the first quarter of 2026 was $19.1 million, an increase of approximately 3% compared to $18.5 million in the first quarter of 2025. Growth was primarily driven by our international business, with international sales of $3.7 million, representing a 41% increase over the prior year period.”
CFO, TELA Bio, Inc. Q1 FY2026 Earnings Call ·
“Revenue for the fourth quarter of 2025 increased 18% year-over-year to $20.9 million, and grew 16% for the full year to $80.3 million, with revenue from Ovatex growing 12% and Ovatex PRS growing 20% for the year.”
CFO, TELA Bio, Inc. Q4 FY2025 Earnings Call ·
“Revenue for the third quarter of 2025 increased 9% year-over-year to $20.7 million, with revenue from OviTex growing 6% and OviTex PRS revenue growing 12% from the prior year period.”
CFO, TELA Bio, Inc. Q3 FY2025 Earnings Call ·
“Revenue for the second quarter of 2025 increased 26% year-over-year to $20.2 million, with revenue from OviTex growing 12% and OviTex PRS revenue growing 53%. OviTex unit sales grew 17% for the quarter, while PRS unit sales grew 40% for the quarter.”
CFO, TELA Bio, Inc. Q2 FY2025 Earnings Call ·
“As you mentioned, revenue for the first quarter of 2025 increased 12% year over year to $18.5 million, with revenue from OviTex growing 15% and 2% for the year.”
CFO, TELA Bio, Inc. Q1 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at TELA Bio, Inc.

Recent activity

Show 7 earlier activities